COVID-19

The regulatory filings include clinical data from a trial of 30,000 participants in the U.S. and Mexico, which found 100% protection against moderate and severe disease and 90.4% efficacy overall, Novavax said.

The U.S. Food and Drug Administration told the company Friday evening that its review could last until January, Moderna said.

University researchers and drug developers in Edmonton are joining forces to create what they say will be Canada's first facility that can take the latest scientific pharmaceutical insights from the lab through clinical trials to the marketplace.